Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 417 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Coronavirus and cancer – July updates July 7, 2020 Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL November 10, 2021 Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for... April 14, 2025 EMA Recommends Granting a Marketing Authorisation for Erdafitinib July 10, 2024 Load more HOT NEWS If You Let It, Nursing Will Change Your Life Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’ Veteran Dresses As Captain America & Brings Joy To Children In... Picking out the patterns: How scientists are finding cancer’s signatures in...
